At a glance
ClinicalIndex Comparison RecordN/ACompleted· 40 enrolled
Drug / intervention
allopurinol +1 moredrug
Likely dose
allopurinol 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Randomized Controlled Study of Uric Acid on the Progression of IgA Nephropathy
In Brief
A clinical study evaluating allopurinol and continue their usual therapy for IgA Nephropathy. Completed, enrolled 40 participants across 1 site.
Detailed Summary
This prospective, randomized controlled study will evaluate the effect of uric acid on the progression of IgA nephropathy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIgA Nephropathy
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2007
First PostedNov 2008
Primary CompletionJun 2009
TodayJul 2026
First PostedNov 19, 2008
Enrollment StartJul 1, 2007
Primary CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 17.6 years ago
Interventions
allopurinoldrug
Patients will receive the lifestyle modification and treatment of allopurinol (300 mg /d) and lifestyle modification for 4 weeks; when the UA level \< 6mg/dl , the dosage changed to 200mg/d.
continue their usual therapyother
Patients will receive lifestyle modification and continue their usual therapy.